Pioneering Breakthroughs in Progeria Therapies

(Cover Illustration by Kimberly Nguyen)

Overview of Progeria

Hutchinson-Gilford Progeria Syndrome (HGPS), commonly known as progeria, is a rare and fatal genetic disorder that causes children to experience accelerated aging. Progeria affects 1 in 4 million births worldwide, and as of 2025, around 400 children and young adults live with the condition. The disease manifests within the first two years of life, leaving patients with progeria with an average life expectancy of 15 to 20 years.

Children with progeria exhibit distinctive physical characteristics such as premature aging, loss of subcutaneous fat or fat under the skin, hair loss, and stunted growth. Affected individuals may also develop severe health complications, with progressive cardiovascular disease, bone abnormalities, dental issues, and hip dislocations. The primary cause of death is often heart disease due to the progressive loss of vascular smooth muscle cells and arterial calcification. Arterial calcification refers to the process by which calcium and phosphate deposits build up within the arterial walls, narrowing and hardening the arteries. Narrow arteries make it harder for blood to reach various body organs, leading to cardiovascular problems.

The LMNA Gene and Progerin Production

Progeria is caused by mutations in the LMNA gene, which is responsible for encoding the lamin A protein. Lamin A is a crucial structural component of the nuclear lamina–the dense web of intermediate filaments that support the cell’s nucleus. Mutations associated with Progeria occur in exon 11, or the 11th protein-coding region of the gene. The location of the mutation in an exon results in the mutation not being removed from the pre-mRNA while it undergoes processing, directly impacting the final protein product. Almost all cases of progeria occur as spontaneous de novo mutations in the gene, meaning the disease is not inherited by a parent and is not dependent on a biological family history. The mutation is an autosomal dominant mutation. Therefore, only one copy of the gene is necessary to develop the condition.

RNA splicing is a process that occurs after the genetic DNA is transcribed into a different type of molecule called mRNA. In RNA splicing, the introns (non-protein coding regions) are cut out while the exons (protein-coding regions) are stitched together. The mutation in exon 11 results in an incorrect splicing of the exons and introns of the pre-mRNA. The incorrect processing produces a truncated, toxic form of the lamin A protein called progerin. In the correct formation of pre-lamin A created by the mRNA, the ZMPSTE24 enzyme can cleave the pre-lamin into the functional form of lamin A. However, progerin lacks 50 amino acids near its C-terminus, or the free carboxyl end of the polypeptide, preventing the formation of the correct form of lamin A.

Due to the inability of the ZMPSTE24 enzyme to cleave the protein, progerin is permanently farnesylated. Farnesylation is a post-translational modification in which a farsenyl group (lipid molecule) is added to the target protein. This farnesyl group helps anchor the functional lamin A inside the cell’s nucleus. However, since progerin is not trimmed correctly, the permanently farnesylated progerin leads to abnormal binding to other lamins and the nuclear envelope, the bilayer that separates the cell nucleus from the outside of the cell’s cytoplasm. The incorrect binding of progerin disrupts the shape of the nuclear envelope, causing severe nuclear instability, which initiates a cascade of cellular deterioration. The deterioration includes apoptosis, or cell death, and contributes to the progressive aging phenotype seen in progeria patients.

Post-Translational Modifications as Potential Therapeutics

Post-translational modifications (PTMs) are chemical changes to a protein after it has been synthesized or translated from mRNA–an RNA molecule derived from DNA in protein synthesis. The modifications play a critical role in regulating the structure, function, and localization of proteins, thus affecting cellular processes. Some examples of PTMs involved in lamin A regulation are farnesylation, acetylation, and phosphorylation. Acetylation is the addition of acetyl groups, or a -COCH3 functional group, to histone proteins–proteins DNA is wrapped around. Acetylation loosens DNA from the histones and makes the DNA more accessible for transcription, which is the process of making an RNA copy of genomic DNA for protein synthesis. Phosphorylation adds a phosphate to the 5’ end of DNA. By adding a local negative charge from the phosphate, the binding of transcription factors to their regulatory sequences is altered and affects the subsequent transcription of the gene. The level of gene transcription directly impacts the amount of protein produced.

One avenue of therapeutic modulation in Progeria is the use of PTMs. Some potential therapies studied in progeria are farnesyltransferase inhibitors (FTIs), deacetylase modulators, and kinase inhibitors. By blocking progerin farnesylation (binding to a lipid molecule), FTIs reduce progerin’s association with the nuclear membrane, alleviating nuclear damage. Deacetylase modulators target histone deacetylases (HDACs), which may influence chromatin structure and gene expression, ultimately improving cellular phenotypes. Kinase inhibitors affect lamin phosphorylation, which can restore nuclear integrity and reduce progerin accumulation.

Studies in progeria cell and animal models suggest that targeting PTMs can mitigate cellular damage, but limitations remain. PTM-based therapies must balance efficacy and precision to avoid disrupting normal lamin A function. Additionally, clinical trials have shown only limited benefits from FTIs in extending lifespan.

DNA Base Editing: A Revolutionary Approach

Recent advancements in gene-editing technologies offer promising avenues for treating progeria at its genetic root. One such approach involves adenine base editors (ABEs), which enable precise nucleotide conversion without inducing double-stranded DNA breaks. ABEs convert adenine-thymine (A•T) base pairs into guanine-cytosine (G•C) base pairs with high specificity, minimizing off-target effects. The mechanism has been tested in multiple models.

In a 2021 study published in Nature, researchers at Harvard tested the efficacy of ABEs at restoring normal RNA splicing and producing a functional lamin A in a progeria model.

In one model, researchers cultured or grew fibroblasts, tissue cells responsible for secreting collagen, from progeria patients. The researchers used a viral vector called a lentivirus to carry ABEs to the fibroblasts. The ABEs resulted in 87-91% of the pathogenic allele. Reduction of progerin levels, mitigation of RNA mis-splicing, and correction of nuclear abnormalities were observed. No detectable off-target mutations were found.

An animal model of progeria was also developed in mice that contained a C to T at position 1824 in the LMNA allele. The ABEs were given to the mice as a single injection with AAV9-mediated or adeno-associated viral delivery. At postnatal day 14, the ABEs had up to a cumulative 60% mutation correction across various organs after six months. The approach also preserved vascular smooth muscle cells, prevented arterial fibrosis, and significantly extended median lifespan from 215 to 510 days.

Findings suggest that in vivo base editing, or base editing within a living organism, holds immense potential in treating HGPS and other genetic disorders by directly correcting the causative mutation.

Therapeutic Implications and Ethical Concerns

Adenine base editing, when combined with other interventions such as FTIs and stem cell transplantation, may provide a comprehensive approach to treating progeria. The first clinical trials using ABEs for progeria began in 2024.

However, despite their promise, gene-editing therapies raise several ethical concerns. One is the long-term safety and unforeseen consequences of genetic modifications. Another concerns the lack of accessibility and affordability of these treatments for patients worldwide. The development of gene therapy raises attention to the broader implications of gene editing for genetic disorders, such as the potential for eugenics.

Future Directions

Future research must refine gene-editing strategies to maximize therapeutic efficacy while minimizing risks. Advances in delivery systems, precision editing techniques, and combination therapies will be crucial in translating these findings into clinical practice. Additionally, continued collaboration between researchers, clinicians, and bioethicists will be essential to ensure that these groundbreaking treatments are safe and ethical.

Progeria, a devastating premature aging disorder, has long been considered untreatable. However, groundbreaking advancements in post-translational modification therapies and gene editing provide newfound hope. With the anticipated clinical trials for base editing on the horizon, the potential to transform the lives of progeria patients is closer than ever. While challenges remain, the progress in genetic medicine paves the way for a future where progeria—and potentially other genetic diseases—can be treated at their source.

Sources: